“Significant Step Forward” for Actinogen’s Alzheimer’s treatment 12-Oct-2022 By Maggie Lynch Clinical data findings from Actinogen’s Phase 2a study measuring the effects of Xanamem in patients with biomarker-positive Alzheimer’s Disease validated company’s ongoing program.